Does Daklinza (daclatasvir) cause side effects?
Daklinza (daclatasvir) is a direct-acting antiviral agent (DAA) used in combination with sofosbuvir (Sovaldi) to treat chronic hepatitis C genotype 1 or 3 infection. It may be used with or without ribavirin (Rebetol, Ribasphere).
Common side effects of Daklinza include
- anemia (when combined with ribavirin),
- elevated lipase,
- drowsiness, and
Serious side effects of Daklinza include
- severe reduction in heart rate in people who were treated with Daklinza and sofosbuvir while also being treated with amiodarone (Cordarone) and
- reactivation of hepatitis B virus (HBV) in people who are infected with HBV and HCV.
Drug interactions of Daklinza include rifampin, carbamazepine, phenytoin, and St. John's wort, which may reduce blood levels of Daklinza and reduce its effectiveness by increasing its metabolism (break-down) in the intestine.
- Other drugs that also may reduce blood levels of Daklinza include nafcillin, bosentan, nevirapine, dexamethasone, efavirenz, atazanavir, darunavir, lopinavir/ritonavir, etravirine, and modafinil.
- Drugs that increase blood levels of Daklinza by reducing its break down in the liver include atazanavir with ritonavir, nelfinavir, indinavir, saquinavir, clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, and voriconazole.
- Daklinza increases blood levels of atorvastatin, rosuvastatin, and other statins.
- Daklinza also increases blood levels of buprenorphine and digoxin.
Daklinza has not been adequately evaluated in pregnant women. However, ribavirin, which may be combined with Daklinza, should not be used by pregnant women or their male partners.
What are the important side effects of Daklinza (daclatasvir)?
Common side effects include:
Other side effects include:
Serious side effects include:
Daklinza (daclatasvir) side effects list for healthcare professionals
If Daklinza and sofosbuvir are administered with ribavirin, refer to the prescribing information for ribavirin regarding ribavirin-associated adverse reactions.
The following serious adverse reaction is described below and elsewhere in the labeling:
- Serious Symptomatic Bradycardia When Coadministered with Sofosbuvir and Amiodarone.
Clinical Trials Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- Approximately 2400 subjects with chronic HCV infection have been treated with the recommended dose of Daklinza in combination with other anti-HCV drugs in clinical trials.
- Six hundred seventy-nine subjects have received a Daklinza and sofosbuvir-based regimen.
- Safety experience from three clinical trials of Daklinza and sofosbuvir with or without ribavirin is presented.
Daklinza And Sofosbuvir
- In the ALLY-3 trial, 152 treatment-naive and treatment-experienced subjects with HCV genotype 3 infection were treated with Daklinza 60 mg once daily in combination with sofosbuvir for 12 weeks.
- The most common adverse reactions (frequency of 10% or greater) were headache and fatigue.
- All adverse reactions were mild to moderate in severity. No subjects discontinued therapy for adverse events.
- In the ALLY-2 trial, 153 treatment-naive and treatment-experienced subjects with HCV/HIV-1 coinfection were treated with Daklinza 60 mg once daily (dose-adjusted for concomitant antiretroviral use) in combination with sofosbuvir for 12 weeks.
- The most common adverse reaction (frequency of 10% or greater) was fatigue.
- The majority of adverse reactions were mild to moderate in severity.
- No subjects discontinued therapy for adverse events. Adverse reactions considered at least possibly related to treatment and occurring at a frequency of 5% or greater in ALLY-3 or ALLY-2 are presented in Table 4.
Table 4: Adverse Reactions (All Severity) Reported at ≥5%
Frequency, Daklinza + Sofosbuvir, Studies ALLY-3 and ALLY-2
|Adverse Reaction||ALLY-3: HCV Genotype 3
|ALLY-2: HCV/HIV-1 Coinfection
Daklinza, Sofosbuvir, And Ribavirin
- In the ALLY-1 trial, 113 subjects with chronic HCV infection, including 60 subjects with Child-Pugh A, B, or C cirrhosis and 53 subjects with recurrence of HCV after liver transplantation, were treated with Daklinza 60 mg once daily in combination with sofosbuvir and ribavirin for 12 weeks.
- The most common adverse reactions (frequency of 10% or greater) among the 113 subjects were
- The majority of adverse reactions were mild to moderate in severity.
- Of the 15 (13%) subjects who discontinued study drug for adverse events, 13 (12%) subjects discontinued ribavirin only and 2 (2%) subjects discontinued all study drugs.
- During treatment, 4 subjects in the cirrhotic cohort underwent liver transplantation.
- Adverse reactions considered at least possibly related to treatment and occurring at a frequency of 5% or greater in either treatment cohort in ALLY-1 are presented in Table 5.
Table 5: Adverse Reactions (All Severity) Reported at ≥5%
Frequency in Either Treatment Cohort, Daklinza + Sofosbuvir + Ribavirin, Study
|Adverse Reaction||Child-Pugh A, B, or C Cirrhosis
|Recurrence after Liver Transplantation
Selected Grade 3 and 4 treatment-emergent laboratory abnormalities observed in clinical trials of Daklinza in combination with sofosbuvir with or without ribavirin are presented in Table 6.
Table 6: Selected Grade 3 and 4 Laboratory
Abnormalities in Clinical Trials of Daklinza + Sofosbuvir ± Ribavirin,
Studies ALLY-3, ALLY2, and ALLY-1
|Parameter||Percent with Abnormality|
|ALLY-3: HCV Genotype 3 Daklinza + Sofosbuvir
|ALLY-2: HCV/HIV-1 Coinfection Daklinza + Sofosbuvir
|ALLY-1: Child-Pugh A, B, or C with Cirrhosis and Post-transplant
Daklinza + Sofosbuvir + Ribavirin
|Hemoglobin (≤8.9 g/dL)||0||0||6%|
|Alanine aminotransferase (ALT) increased (≥5.1 x ULN)||0||0||2%|
|Aspartate aminotransferase (AST) increased (≥5.1 x ULN)||0||0||3%|
|Total bilirubin increased (≥2.6 x ULN)||0||5%a||8%|
|Lipase increased (≥3.1 x ULN)||2%||4%||4%|
|a In the ALLY-2 trial, Grade 3 and 4 increases in total bilirubin were observed only in subjects receiving concomitant atazanavir.|
The following adverse reactions have been identified during postapproval use of Daklinza. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Serious symptomatic bradycardia has been reported in patients taking amiodarone who initiate treatment with a sofosbuvir-containing regimen.
What drugs interact with Daklinza (daclatasvir)?
Potential For Other Drugs To Affect Daklinza
- Daclatasvir is a substrate of CYP3A. Therefore, moderate or strong inducers of CYP3A may decrease the plasma levels and therapeutic effect of daclatasvir.
- Strong inhibitors of CYP3A (eg, clarithromycin, itraconazole, ketoconazole, ritonavir) may increase the plasma levels of daclatasvir.
Potential For Daklinza To Affect Other Drugs
- Daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP).
- Administration of Daklinza may increase systemic exposure to medicinal products that are substrates of P-gp, OATP 1B1 or 1B3, or BCRP, which could increase or prolong their therapeutic effect or adverse reactions (see Table 7).
Established And Other Potentially Significant Drug Interactions
- Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact the safe and effective use of concomitant medications.
- For example, altered blood glucose control resulting in serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.
- Management of hypoglycemia in these cases required either discontinuation or dose modification of concomitant medications used for diabetes treatment.
- Frequent monitoring of relevant laboratory parameters (e.g. International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of concomitant medications such as cytochrome P450 substrates with a narrow therapeutic index (e.g. certain immunosuppressants) is recommended to ensure safe and effective use.
- Dose adjustments of concomitant medications may be necessary.
- Refer to the prescribing information for other agents in the regimen for drug interaction information. The most conservative recommendation should be followed.
- Please also refer to Section 4 (Contraindications) and Section 12.3 (Pharmacokinetics) for complete information on all drug interactions.
- Table 7 provides clinical recommendations for established or potentially significant drug interactions between Daklinza and other drugs. Clinically relevant increase in concentration is indicated as “?” and clinically relevant decrease as “?” for drug interaction data.
Table 7: Established and Other Potentially Significant
|Concomitant Drug Class: Drug Name||Effect on Concentrationa||Clinical Comment|
|HIV antiviral agents|
Atazanavir with ritonavirb
|↑ Daclatasvir||Decrease Daklinza dose to 30 mg once daily.|
|↑ Daclatasvir||Decrease Daklinza dose to 30 mg once daily except with darunavir combined with cobicistat.|
|Non-nucleoside reverse transcriptase inhibitors (NNRTI):
|↓ Daclatasvir||Increase Daklinza dose to 90 mg once daily.|
|Strong CYP3A inhibitors (see also HIV antiviral agents)|
|Examples: clarithromycin, itraconazole, ketoconazole,b nefazodone, posaconazole, telithromycin, voriconazole||↑Daclatasvir||Decrease Daklinza dose to 30 mg once daily when coadministered with strong inhibitors of CYP3A.|
|Moderate CYP3A inducers (see also HIV antiviral agents)|
|Examples: bosentan, dexamethasone, modafinil, nafcillin, rifapentine||↓ Daclatasvir||Increase Daklinza dose to 90 mg once daily when coadministered with moderate inducers of CYP3A.|
|Dabigatran etexilate mesylate||↑ Dabigatran||Use of Daklinza with dabigatran etexilate is not recommended in specific renal impairment groups, depending on the indication. Please see the dabigatran prescribing information for specific recommendations.|
|Antiarrhythmic: Amiodarone||Amiodarone: effects unknown||Coadministration of amiodarone with Daklinza in combination with sofosbuvir is not recommended because it may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. If coadministration is required, cardiac monitoring is recommended.|
|Antiarrhythmic: Digoxinb||↑Digoxin||Patients already receiving daclatasvir initiating digoxin: Initiate treatment using the lowest appropriate digoxin dosage. Monitor digoxin concentrations; adjust digoxin doses if necessary and continue monitoring.
Patients already receiving digoxin prior to initiating daclatasvir: Measure serum digoxin concentrations before initiating daclatasvir. Reduce digoxin concentrations by decreasing digoxin dosage by approximately 15% to 30% or by modifying the dosing frequency and continue monitoring.
|HMG-CoA reductase inhibitors:|
|Atorvastatin||↑ Atorvastatin||Monitor for HMG-CoA reductase inhibitor- associated adverse events such as myopathy.|
|Narcotic Analgesic/Treatment of Opioid Dependence|
|buprenorphine buprenorphine/naloxone||↑ buprenorphine ↑norbuprenorphine||For buprenorphine or buprenorphine/naloxone, no adjustment is needed, but clinical monitoring for buprenorphine-associated adverse events is recommended.|
|a The direction of the arrow (↑ = increase, ↓ =
decrease) indicates the direction of the change in pharmacokinetic parameters.
b These interactions have been studied.
Drugs Without Clinically Significant Interactions With Daklinza
- Please see prescribing information for information regarding anticipated interactions that are not clinically relevant.
- Based on the results of drug interaction trials, no clinically relevant changes in exposure were observed for cyclosporine, darunavir (with ritonavir), dolutegravir, escitalopram, ethinyl estradiol/norgestimate, lopinavir (with ritonavir), methadone, midazolam, tacrolimus, or tenofovir with concomitant use of daclatasvir.
- No clinically relevant changes in daclatasvir exposure were observed with cyclosporine, darunavir (with ritonavir), dolutegravir, escitalopram, famotidine, lopinavir (with ritonavir), omeprazole, sofosbuvir, tacrolimus, or tenofovir.
- No dosage adjustment for daclatasvir is necessary with darunavir/cobicistat or moderate CYP3A inhibitors, including atazanavir (unboosted), fosamprenavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, or verapamil.
Multimedia: Slideshows, Images & Quizzes
Hepatitis C, Hep B, Hep A: Symptoms, Causes, Treatment
Hepatitis C, B, and A are viruses that cause liver inflammation. Hepatitis B vaccines and hepatitis A vaccines are available....
Liver Health: 14 Best and Worst Foods for Your Liver
Get some simple diet tips to keep your liver healthy, including the best veggies to keep disease away and some snacks you'll want...
Hepatitis C (Hep C): Symptoms, Treatments, Antivirals
What is hepatitis C (Hep C, HVC)? Learn about hepatitis C symptoms, how you get Hep C, contagiousness, and treatment for...
Hepatitis: Surprising Things That Can Damage Your Liver
Alcohol and acetaminophen are well-known liver dangers, but what else can be harmful? WebMD says some of them may surprise you.
Hepatitis: How Do You Get Hepatitis A, B, and C?
Hepatitis C virus and hepatitis B can make an infected person very sick and they are risk factors for liver cancer, liver...
Hepatitis A Quiz: Test Your Medical IQ
How many types of hepatitis are there, and what is different about hepatitis A? Take this quiz to find out!
Hepatitis C Quiz: What is Hepatitis C?
How many Americans have hepatitis C? Take this quiz to learn the facts about this chronic disease.
Picture of Hepatitis B
Inflammation of the liver due to the hepatitis B virus (HBV), once thought to be passed only through blood products. See a...
Related Disease Conditions
Hepatitis (Viral Hepatitis A, B, C, D, E, G)
Hepatitis is most often viral, due to infection with one of the hepatitis viruses (A, B, C, D, E, F (not confirmed), and G) or another virus (such as those that cause infectious mononucleosis, cytomegalovirus disease). The main nonviral causes of hepatitis are alcohol and drugs. Many patients infected with hepatitis A, B, and C have few or no symptoms of illness. For those who do develop symptoms of viral hepatitis, the most common are flu-like symptoms including: loss of appetite, nausea, vomiting, fever, weakness, tiredness, and aching in the abdomen. Treatment of viral hepatitis is dependent on the type of hepatitis.
Hepatitis C (HCV, Hep C)
Hepatitis C is an inflammation of the liver due to the hepatitis C virus (HCV), which is usually spread by blood transfusion, hemodialysis, and needle sticks, especially with intravenous drug abuse. Symptoms of chronic hepatitis include fatigue, fever, muscle aches, loss of appetite, and fever. Chronic hepatitis C may be cured in most individuals with drugs that target specific genomes of hepatitis C.
Hepatitis A (HAV, Hep A)
Hepatitis means inflammation of the liver. Hepatitis A (HAV, Hep A) is one type of liver disease caused by a virus. Since hepatitis A is a virus, it can pass from person to person from eating or drinking contaminated food or coming into contact with contaminated materials containing the virus. Symptoms of hepatitis A include stomach pain, diarrhea, dark yellow urine, jaundice, and more. There is a vaccine to prevent contracting hepatitis A.
Hepatitis B (HBV, Hep B)
The hepatitis B virus (HBV, hep B) is a unique, coated DNA virus belonging to the Hepadnaviridae family of viruses. The course of the virus is determined primarily by the age at which the infection is acquired and the interaction between the virus and the body's immune system. Successful treatment is associated with a reduction in liver injury and fibrosis (scarring), a decreased likelihood of developing cirrhosis and its complications, including liver cancer, and a prolonged survival.
Hepatitis A and B Vaccinations
Hepatitis A and hepatitis B are the two most commnon viruses that infect the liver. Hepatitis A and Hepatitis B can be prevented and treated with immunizations (vaccinations) such as Havrix, Vaqta, Twinrix, Comvax, Pediarix, and hepatitis b immune globulin (HBIG).
Is Hepatitis Contagious?
Hepatitis means "inflammation of the liver," and there are several different types of such as A, B, C, D, and E. Some types of hepatitis are contagious and some types are not. Hepatitis symptoms vary upon the type of disease; however, the following symptoms may develop in someone with hepatitis: fatigue, nausea and vomiting, abdominal pain and discomfort, jaundice (yellowing of the skin and whites of the eyes), and loss of appetite. Treatment for hepatitis depends upon the cause. Some types of hepatitis have a vaccine to prevent spread of disease such as hepatitis A and B.
Is Hepatitis C Contagious?
Hepatitis C or hep C causes acute and chronic liver disease. Hep C is a form of liver disease with symptoms like fatigue, jaundice, nausea and vomiting, anorexia, and abdominal discomfort. Hepatitis C is a contagious viral infection caused by persons sharing drug needles, surgical instruments that have not been properly sanitized, and organ transplantation.
Is Hepatitis B Contagious?
Hepatitis B is a type of liver infection. Hepatitis B is spread through person-to-person contact or through personal items like razors, toothbrushes, etc. Symptoms of hepatitis B include fever, yellowish skin (jaundice), dark urine, fatigue, nausea, and vomiting. There is no drug to cure hepatitis B; however, there is a hepatitis B vaccine available.
Hepatitis C Cure (Symptoms, Transmission, Treatments, and Cost)
Hepatitis is inflammation of the liver. There are a variety of toxins, diseases, illicit drugs, medications, bacterial and viral infections, and heavy alcohol use can case inflammation of the liver. Hepatitis C viral infection (HCV) is one type of hepatitis. According to the CDC, in 2014 there were an estimated 30,500 cases of acute hepatitis C infections in the US. An estimated 2.7-3.9 million people in the US have chronic hepatitis C. The virus is spread from person-to-person via blood-to-blood contact. Symptoms of HCV infection include joint pain, jaundice, dark urine, nausea, fatigue, fever, loss of appetites, clay colored stool. Hepatitis C can be cured with medications in most people. There is no vaccine against the hepatitis C virus.
Is Hepatitis A Contagious?
Hepatitis means inflammation of the liver. Hepatitis A is one type of hepatitis. Hepatitis is transmitted through person to person contact, contaminated ice, vegetables, fruits, and untreated water. Hepatitis A can be prevented by the hepatitis A vaccine. Symptoms of hepatitis A may include nausea and/or vomiting, fever, loss of appetite, abdominal pain, dark urine, clay-colored stools, jaundice (yellowish color to skin and/or eyes, or joint pain.
Hepatitis E Viral Infection
Hepatitis E (hep E) is a type of hepatitis viral infection that includes hepatitis A, B, C, D, F, which is caused by the hepatitis E virus. Usually, you get (transmitted) hepatitis E from eating or drinking dirty or contaminated water. Hepatitis E can be very serious, especially if a woman is pregnant. Up to ¼ of women who are pregnant with the hep E virus can die from the infection. The signs and symptoms of hepatitis E infection are nausea and vomiting, brown or dark urine, stool changes jaundice (yellow eyes and skin), pain in the right side of the abdomen, dark or brown urine, and light-colored stool. Some people with hep E don’t have any symptoms so they don’t know that they are contagious. It takes about 6 weeks to recover from hep E. A person who has any type of hepatitis, including hepatitis E, should not drink any alcohol. Hep E complications are rare, but when they do occur they include severe (“fulminant”) hepatitis, liver failure, and death. Currently, no specific drugs or treatments are available for hepatitis E. Moreover, the only hepatitis E vaccine currently is available in China. Avoid alcohol, keep hydrated, and getting rest are home remedies for hepatitis E. Talk to your doctor before taking any over-the-counter (medications), especially those containing acetaminophen (Tylenol and others). Usually, the prognosis and life expectancy for hepatitis E after recovery is good. Most people do not have long term liver problems from the infection.
What Causes Hepatitis?
Hepatitis is inflammation of the liver. It can occur due to a variety of factors, but the most common cause is a virus infection. The types of hepatitis are hepatitis A, B, C, D, and E. Hepatitis can be acute (short-term) or chronic (long-term) and can have fatal complications. Early diagnosis, treatment and lifestyle modification can slow or inhibit the progression of the disease and reduce complications.
Treatment & Diagnosis
- Hepatitis C FAQs
- Hepatitis A FAQs
- Hepatitis C News Release
- Chronic Viral Hepatitis, Alcoholism, Cirrhosis Linked to Liver Cancer
- Hepatitis A at Jam Band Concerts Alert
- Hepatitis C: Nightmare in Vegas
- IBS, GERD, Hepatitis C: Doctors Dialogue
- How common is Hepatitis C?
- How is diagnosis of Hepatitis C made?
- Hepatitis C : Can it be sexually transmitted?
- Hepatitis C: What blood tests?
- Hepatitis C genotypes
- Hepatitis C Treatments
- Hepatitis C: Most effective treatment
- Hepatitis C: Reasons for treating
- Hepatitis C: Interferon/ribavarin side effects
- Hepatitis C: Good candidates for treatment
- Do you treat hepatitis C patients with normal liver tests?
- Hepatitis C: Not Good Candidates for Treatment?
- Hepatitis C: Diet and Vitamins
- Hepatitis C: Should patients receive immunizations
- Hepatitis C treatment relapse
- What to do for relapsers after hepatitis C treatment?
- Hepatitis C: What is unique about hepatitis C?
- Can You Be Allergic to Ceclor for Hepatitis B?
- Can You Treat Hepatitis B With Aids Drug Lamivudine?
- Does Hepatitis B Cause Liver Cancer?
- What Kind of Doctor Do I See for Hepatitis C?
- Can The Hepatitis C Virus Survive Outside the Body?
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.